#United States #Palo Alto #Guardant Health #Colorectal Cancer #Shield Test

Guardant Health's Initiative for Colorectal Cancer Awareness

In a proactive move to combat colorectal cancer (CRC), Guardant Health, Inc. has unveiled a community grant program ahead of CRC Awareness Month in March. This initiative aims to improve access to crucial screening tests, ultimately encouraging increased participation among at-risk populations.

Purpose of the Grant Program

The newly established Community Colorectal Cancer Screening Grant Program is set to contribute significantly to public health. Through this program, Guardant Health will provide selected organizations, including patient advocacy groups, non-profits, and public health associations, with up to 100 Shield tests at no cost to either the organizations or the patients involved. This grant is designed to bolster community health fairs, screening events, and educational outreach initiatives scheduled throughout March.

The Shield test is not just any screening method; it stands out as the first and only blood test approved by the FDA as a primary screening option for adults aged 45 and older, specifically for those at average risk. By enabling this convenient and patient-friendly alternative, Guardant Health aims to address obstacles often faced with traditional screening methods, which can deter individuals from undergoing necessary tests.

Importance of Screening in Tackling Colorectal Cancer

Colorectal cancer remains one of the leading causes of cancer-related fatalities in the United States. However, it is among the most preventable cancers through proper and timely screening. Guardant Health's program underscores the company's dedication to dismantling barriers to screening, particularly within underserved communities, and empowering organizations that are at the forefront of enhancing access to these vital health services.

Guardant encourages organizations that excel in community engagement and health outreach to apply for the grant. Interested groups can access the Request for Proposals (RFP) and complete their applications through Guardant's platform. The deadline for application submission is February 17, 2026, with acceptance notifications being communicated on February 20, 2026.

Details of the Shield Test

The Shield test is a non-invasive, methylation partitioning cell-free DNA (mp-cfDNA) blood screening designed to detect colorectal cancer indicators in a simple blood sample. Specifically tailored for individuals at average risk aged 45 and older, it is an inclusive testing option recommended alongside other non-invasive methods. If a positive result arises from the Shield test, it necessitates further evaluation, including a colonoscopy.

About Guardant Health

Guardant Health is a prominent player in the field of precision oncology. Since its inception in 2012, the company has aimed to improve patient care and expedite advancements in cancer treatment. Guardant specializes in providing critical insights through its advanced blood and tissue analyses, aimed at enhancing survival rates and outcomes across all cancer care stages, from initial screening to treatment selection.

With ongoing commitment from Guardant Health, the importance of community health initiatives, particularly in the realm of colorectal cancer screening, cannot be overstated. Such proactive measures not only save lives but pave the way for a healthier future.

For additional queries about the grant application process, stakeholders are invited to reach out via email at [email protected].

To learn more about Guardant Health and its innovative testing solutions, visit their official website or follow them on social media platforms like LinkedIn, Twitter, and Facebook.